BRAF and neoplasm: Thus, FOLFOXIRI plus bevacizumab is currently regarded as a standard first-line option in mCRCs, especially as a neoadjuvant treatment in fit patients with initially unresectable diseases or in patients with good ECOG PS and a poor prognosis tumor (i.e., right colon or BRAF-mutated tumors).